全文获取类型
收费全文 | 223191篇 |
免费 | 6003篇 |
国内免费 | 646篇 |
专业分类
耳鼻咽喉 | 3073篇 |
儿科学 | 8345篇 |
妇产科学 | 7032篇 |
基础医学 | 28762篇 |
口腔科学 | 6165篇 |
临床医学 | 19170篇 |
内科学 | 40324篇 |
皮肤病学 | 5005篇 |
神经病学 | 13680篇 |
特种医学 | 11281篇 |
外国民族医学 | 98篇 |
外科学 | 32308篇 |
综合类 | 2064篇 |
现状与发展 | 2篇 |
一般理论 | 41篇 |
预防医学 | 19353篇 |
眼科学 | 4851篇 |
药学 | 15280篇 |
2篇 | |
中国医学 | 248篇 |
肿瘤学 | 12756篇 |
出版年
2021年 | 809篇 |
2018年 | 4183篇 |
2017年 | 4344篇 |
2016年 | 3698篇 |
2015年 | 5602篇 |
2014年 | 5237篇 |
2013年 | 4769篇 |
2012年 | 11860篇 |
2011年 | 6799篇 |
2010年 | 3336篇 |
2009年 | 4862篇 |
2008年 | 3787篇 |
2007年 | 4653篇 |
2006年 | 4784篇 |
2005年 | 12918篇 |
2004年 | 14278篇 |
2003年 | 9718篇 |
2002年 | 4867篇 |
2001年 | 4896篇 |
2000年 | 2168篇 |
1999年 | 6293篇 |
1998年 | 829篇 |
1992年 | 7107篇 |
1991年 | 7328篇 |
1990年 | 7560篇 |
1989年 | 7127篇 |
1988年 | 6643篇 |
1987年 | 6399篇 |
1986年 | 6108篇 |
1985年 | 5378篇 |
1984年 | 3731篇 |
1983年 | 3038篇 |
1982年 | 1098篇 |
1981年 | 883篇 |
1980年 | 949篇 |
1979年 | 3947篇 |
1978年 | 2458篇 |
1977年 | 1870篇 |
1976年 | 1644篇 |
1975年 | 2536篇 |
1974年 | 3190篇 |
1973年 | 2792篇 |
1972年 | 2837篇 |
1971年 | 2791篇 |
1970年 | 2599篇 |
1969年 | 2494篇 |
1968年 | 2250篇 |
1967年 | 2180篇 |
1966年 | 1918篇 |
1965年 | 1149篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
Christian Holm Hansen Shelley Lees Saidi Kapiga Janet Seeley Tony Barnett 《Global public health》2020,15(3):402-413
ABSTRACTMeasuring hope reliably and accurately remains an important research objective, not least in less prosperous settings where ‘holding on to hope’ may be critically important in the struggle against adverse life conditions. The State Hope Scale was designed for use in the US. Despite reported application in diverse cultures and using translations the scale has not been extensively validated outside US populations. This study contributes to a larger project exploring the measurement of hope and provides a critique of Snyder’s scale as used in a Tanzanian female population of 1021 urban microfinance participants. We evaluate the scale’s validity through assessment of the empirical distribution of scores, item response profiles, internal consistency and discriminatory ability. Participants mostly scored very high and many reached very near the maximum attainable score. Hardly any endorsed the negative half of the response scale. Several problems are discussed including poor discrimination and strong evidence of acquiescence response bias. We also found little association of the scale scores with hypothesised correlates of hope. Future improvements on the measurement of hope are recommended, especially in studies outside the narrow Western context in which the scale was devised. 相似文献
7.
ABSTRACTThis work collates data from the analysis of complex mixtures analysed in STRmix during routine no-suspect volume crime work. It interrogates the upload rate for these types of mixtures and which component of the profile has been able to be interpreted for upload. The number of profiles giving multiple uploads and the amount of replicate PCR analysis has been collated. 相似文献
8.
9.
10.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献